Jefferies Maintains a Buy on Enovis (ENOV), Sets a $60 PT

Enovis Corporation (NYSE:ENOV) is one of the 13 Small Cap Stocks Analysts Are Bullish On. On May 28, Jefferies analyst Young Li maintained a Buy rating on Enovis Corporation (NYSE:ENOV) and set a price target of $60.00. The positive rating was based on several key factors, as the company reported a strong start to the year with notable growth figures in fiscal Q1 2025.

Its net sales for the quarter grew 8% on a reported basis compared to the same quarter in 2024, while adjusted EBITDA reached $99 million, or 17.7% of sales. This translates to a 160 basis points growth compared to last year.

The analyst attributed the growth to the company’s successful commercial execution and integration efforts, as well as additional potential from cross-selling opportunities and new product launches.

Enovis Corporation (NYSE:ENOV) is also increasing its free cash flow conversion and expanding margins, which positions it well for future profitability. The analyst further reasoned that the company has an attractive valuation and is trading below its peers, which points toward the potential for multiple expansions.

Enovis Corporation (NYSE:ENOV) is a medical technology growth company that develops clinically differentiated solutions to transform workflows and generate better patient outcomes. The company operates through the Prevention & Recovery and Reconstructive segments.

While we acknowledge the potential of ENOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.